Riskpilot← Back to searchSign inGet full accessAmerisis AB
ABActiveOrg 5568229297Timotejvägen 10General medical practice activities · NACE 8621Est. 20100 employees
Revenue 2024
SEK 143K
-116% vs 2023
EBITDA margin
37.1%
+105% vs 2023
Equity ratio
39.5%
Financial strength
Net profit 2024
SEK 31K
+106% vs 2023
| Revenue | SEK 143K | -116% |
| EBITDA | SEK 53K | +105% |
| Net profit | SEK 31K | +106% |
| Total assets | SEK 2,4M | +70% |
| Equity | SEK 939K | +4% |
| Employees | 0 | — |
Legal name
Amerisis AB
Org number
5568229297
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
1 november 2010
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-08-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Amer Wåhlin, Isis
Company purpose
Föremålet för bolagets verksamhet är att bedriva utveckling, forskning, utbildning, interimstjänster och konsultationer inom hälso- och sjukvårdsområdet samt därmed förenlig verksamhet.
Address
Timotejvägen 10
Email
isis@2heal.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 167 | 209 | 2 152 | −907 | 143 |
| Staff expenses | — | — | −0 | — | — |
| EBITDA | −238 | 115 | 2 128 | −1 050 | 53 |
| Depreciation & amort. | −0 | −0 | — | — | −0 |
| EBIT | −238 | 115 | 2 128 | −1 050 | 53 |
| Net financials | −4 | −1 | −1 | −12 | −22 |
| Profit before tax | −115 | 115 | 1 590 | −524 | 31 |
| Tax | −0 | −5 | −319 | — | −0 |
| Net profit | −115 | 110 | 1 271 | −524 | 31 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 181 | 194 | 2 296 | 1 397 | 2 380 |
| Equity | 51 | 161 | 1 431 | 907 | 939 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 130 | 33 | 327 | 490 | 1 441 |
| Total debt | 130 | 33 | 327 | 490 | 1 441 |
EBITDA margin
37.1%
This company
15.8%
Market median
+135% vs market
20202024
Equity ratio
39.5%
This company
38.2%
Market median
+3% vs market
20202024
Return on equity
3.3%
This company
18.4%
Market median
-82% vs market
20202024
Net profit margin
21.7%
This company
8.1%
Market median
+168% vs market
20202024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20202024
Debt / equity
1.53×
This company
0.62×
Market median
-147% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-09-01 – 2020-08-31
| Name | Role | Member since |
|---|---|---|
| Former (1) | ||
ME Audit | Audit | 2020 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Board of Directors | 2020 – 2021 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Amerisis AB 
2Heal medical ABBoard members of Amerisis AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mats Erik Dahlström | Audit | 0 companies |
| Isis Amer Wåhlin | Board of Directors | 0 companies |
| Nadia Elisabeth Märta Wåhlin | Deputy Board Member | 0 companies |
| Marc Erik Amer Wåhlin | Board of Directors | 0 companies |
| Lars Erik Tage Wåhlin | Deputy Board Member | 0 companies |